Transient Depressive Relapse Induced by Catecholamine Depletion: Potential Phenotypic Vulnerability Marker?
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although state-related alterations in catecholamine function have been well-described in depressed subjects, enduring abnormalities have been less reliably identified. In our study, medication-free subjects with fully remitted major depression underwent a paradigm of catecholamine depletion, via use of the tyrosine hydroxylase inhibitor alpha-methylparatyrosine. METHOD: Subjects underwent 2 sets of testing conditions in a double-blind, random-ordered, crossover design, approximately 1 week apart. They underwent active catecholamine depletion (via oral administration of 5 g alpha-methylparatyrosine) or sedation-controlled, sham catecholamine depletion (via oral administration of 250 mg diphenhydramine hydrochloride), during a 2-day observation. Serial mood ratings and blood samples were obtained. RESULTS: Fourteen subjects completed the active testing condition; 13 completed sham testing. Subjects experienced marked, transient increases in core depressive and anxiety symptoms, as demonstrated by a mean 21-point increase on Hamilton Depression Rating Scale scores. Furthermore, 10 (71%) of 14 subjects fulfilled relapse criteria during active testing, whereas 1 (8%) of 13 subjects did so during sham testing. The severity of the depressive reaction correlated with baseline plasma cortisol levels (r = 0.59; P =.04). CONCLUSIONS: Euthymic, medication-free subjects with a history of major depression demonstrate significant depressive symptoms when undergoing testing with alpha-methylparatyrosine. This depressive reaction may represent a reliable marker for a history of depression. Further work is needed to clarify the significance of this finding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coplan, J. D., Andrews, M. W., Rosenblum, L. A., Owens, M. J., Friedman, S., Gorman, J. M., & Nemeroff, C. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1619 · Cited by 649
Miller, H. L. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020031005 · Cited by 192
Self-citationBanki, C. M., Karmacsi, L., Bissette, G., & Nemeroff, C. B. (1992) · European Neuropsychopharmacology · doi:10.1016/0924-977x(92)90019-5 · Cited by 149 · cited 3×
“This finding is consistent with a mixed literature suggesting that abnormalities of cortisol regulation (ie, higher levels after dexamethasone administration) may correlate with higher basal levels of MHPG.49 Furthermore, such persistent dexamethasone nonsuppression in treatment responders is associated with a vulnera…”
BackgroundMelia, K. R., Rasmussen, K., Terwilliger, R. Z., Haycock, J. W., Nestler, E. J., & Duman, R. S. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09748.x · Cited by 133 · cited 1×
“Conversely, all classes of antidepressant medications were found to reduce TH levels in the LC of rodents,(38) whereas stress and catecholaminedepleting agents increase TH levels.(39,40) Importantly, a-methylparatyrosine administration may mediate behavioral effects via disruption of dopaminergic function (as would be…”
Background
Cited by
The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
Gottesman, I. I., & Gould, T. D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.636 · Cited by 5,615
Gold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
Depression, Stress, and Anhedonia: Toward a Synthesis and Integrated Model
Pizzagalli, D. A. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185606 · Cited by 1,155
“These findings were replicated by Berman et al. (1999), who showed that AMPT administration in euthymic subjects with an MDD history led to a transient but marked reinstantiation of depressive symptoms.”
BackgroundDiscovering Endophenotypes for Major Depression
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300506 · Cited by 1,123
Self-citationRuhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Psychiatric endophenotypes and the development of valid animal models
Gould, T. D., & Gottesman, I. I. (2006) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2005.00186.x · Cited by 512
Charney, D. S., & Manji, H. K. (2004) · Science's STKE · doi:10.1126/stke.2252004re5 · Cited by 429
Self-citationWhat has serotonin to do with depression?
Cowen, P. J., & Browning, M. (2015) · World Psychiatry · doi:10.1002/wps.20229 · Cited by 374
The importance of norepinephrine in depression
Briley, M., & Chantal, M. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19619 · Cited by 373
“18,44,45”
Bernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Akil, H., & Watson, S. J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.44 · Cited by 372
Berman, R. M., Narasimhan, M., Sanacora, G., Miano, A. P., Hoffman, R. E., Hu, X. S., Charney, D. S., & Boutros, N. N. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00243-7 · Cited by 282
Self-citationEndophenotypes in bipolar disorder
Lenox, R. H., Gould, T. D., & Manji, H. K. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10360 · Cited by 264
The global burden of mental disorders.
Ustün, T. B. (1999) · American Journal of Public Health · doi:10.2105/ajph.89.9.1315 · Cited by 258
Hasler, G., Fromm, S., Carlson, P. J., Luckenbaugh, D. A., Waldeck, T., Geraci, M., Roiser, J. P., Neumeister, A., Meyers, N., Charney, D. S., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.5.521 · Cited by 209
“However, the previous study of CD in unmedicated RMDD subjects demonstrated that AMPT resulted in significantly greater effects on the depressed mood and anxiety items of the depression rating scale than did the sedative diphenhydramine (administered as an active placebo).(5) In our study, the effect of sedation was p…”
MethodResultSelf-citationMeyer, J. H., Wilson, A. A., Sagrati, S., Miler, L., Rusjan, P., Bloomfield, P. M., Clark, M., Sacher, J., Voineskos, A. N., & Houle, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.156 · Cited by 182
Bhagwagar, Z., & Cowen, P. J. (2008) · Psychological Medicine · doi:10.1017/s0033291707001250 · Cited by 124
Roiser, J. P., McLean, A., Ogilvie, A. D., Blackwell, A. D., Bamber, D. J., Goodyer, I., Jones, P. B., & Sahakian, B. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300659 · Cited by 96
“…hydroxylase inhibitor alpha-methylparatyrosine (AMPT), which causes depletion of both DA and NA, causes depressive relapse in patients recovered on selective noradrenaline reuptake inhibitors (SNRIs), but not those recovered on SSRIs (Berman et al, 1999; Bremner et al, 2003; Miller et al, 1996).”
BackgroundInfluentialStriatal structure and function in mood disorders: a comprehensive review
Marchand, W. R., & Yurgelun‐Todd, D. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00874.x · Cited by 91
Harmer, C. J., Perrett, D. I., Cowen, P. J., & Goodwin, G. M. (2001) · Psychopharmacology · doi:10.1007/s002130000654 · Cited by 73
“The present action of propranolol upon the processing of sadness is consistent with the involvement of noradrenaline in mood and affect supported most directly by the antidepressant effects of specific noradrenaline reuptake inhibitors (Schatzberg 2000) and the effects of catecholamine depletion upon mood in drug free…”
BackgroundResultHoman, P., Neumeister, A., Nugent, A. C., Charney, D. S., Drevets, W. C., & Hasler, G. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.25 · Cited by 46
Self-citation
Metadata
- Authors
- Berman, R. M., Narasimhan, M., Miller, H. L., Anand, A., Cappiello, A., Oren, D. A., Heninger, G. R., & Charney, D. S.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1999-05-01
- Volume
- 56
- Issue
- 5
- Pages
- 395
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2093456810
- Cited by
- 118
- References
- 4
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.